Journal of Internal Medicine Concepts & Practice ›› 2024, Vol. 19 ›› Issue (03): 185-187.doi: 10.16138/j.1673-6087.2024.03.06

• Case report • Previous Articles     Next Articles

Acute myeloid leukemia with CEBPA double mutation combined with GATA2 germline mutation: one case report

AN Huihui1,2, WU Tao1,2(), LI Yunyun2, LIU Wenhui2, TIAN Sirui2, LIU Yang2, GAO Mingmin2   

  1. 1. The Second Hospital of Lanzhou University (the Second Clinical Medical College), Lanzhou 730030, China
    2. Department of Hematology, the 940th Hospital of the Joint Logistics Support Force of Chinese People’s Liberation Army, Lanzhou 730050, China
  • Received:2023-12-25 Online:2024-06-28 Published:2024-09-09

Abstract:

The patient was diagnosed as acute myeloid leukaemia with CEBPA double mutation, GATA2 and IKZF1 mutation in 2021, and relapsed after giving two courses of IA treatment (idarubicin, cytosine arabinoside). There was transient remission after four additional courses of azacitidine combined with venetoclax. The patient relapsed again due to lack of regular treatment. This paper mainly analyses the therapeutic and prognostic role of CEBPA double mutation combined with GATA2 germline mutation in acute myeloid leukaemia.

Key words: GATA2 mutation, Acute myeloid leukaemia, Haematopoietic stem cell transplantation, Haematological malignancies, CEBPA

CLC Number: